Nebacumab Explained

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]

Notes and References

  1. Derkx B, Wittes J, McCloskey R . Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group . Clinical Infectious Diseases . 28 . 4 . 770–7 . April 1999 . 10825037 . 10.1086/515184 . free .
  2. https://web.archive.org/web/20091107133217/http://apps.who.int/medicinedocs/en/d/Js4902e/4.1.262.html#Js4902e.4.1.262 WHO: Consolidated List of Products

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nebacumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.